CPI Begins Construction on Medicines Manufacturing Innovation Centre

Published 11-4-2020
  • CPI - Medicines Manufacturing Innovation Centre
  • CPI - Medicines Manufacturing Innovation Centre
  • CPI - Medicines Manufacturing Innovation Centre

    Courtesy of CPI.

  • CPI - Medicines Manufacturing Innovation Centre

    Courtesy of CPI.

CPI began construction in October of 2020 on the Medicines Manufacturing Innovation Centre in Inchinnan in the United Kingdom. Created in collaboration with the University of Strathclyde, GSK, and AstraZeneca, the £42 million facility will enable the development of new pharmaceutical production methods that will be proven at scale in a GMP environment. Providing an interactive hub where industry, academic, healthcare, and regulatory partners can develop novel techniques for the manufacture of patient-centric medicines, the project will accelerate the delivery of affordable therapeutics to medical providers and patients. Private companies will be able to access the center to evaluate, test, and prototype processes using an array of advanced Industry 4.0 technologies, including continuous, digital, and autonomous manufacturing.

BakerHicks is providing architectural and engineering services for the development with Interserve as construction manager. UK Research and Innovation (UKRI) is supplying £13 million in funding for the project, accompanied by £15 million from Scottish Enterprise and £7 million from both GSK and AstraZeneca. The Medicines Manufacturing Innovation Centre will eventually house over 80 staff in both technical and non-technical roles. Completion is expected in late 2021 with operations commencing in early 2022.